Navigation Links
Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
Date:5/20/2009

arch program at the University of Cincinnati College of Medicine. "Lurasidone has the potential to be an important new therapeutic option for patients with schizophrenia."

Lurasidone's effect on weight was similar to placebo (median change 0.3 kg for overall lurasidone group vs. 0 kg for placebo) as was its effect on lipid and glucose measures. Lurasidone was also well tolerated with a lower overall discontinuation rate (31%) compared to placebo (43%) and few adverse event-related discontinuations (6% and 2% for the overall lurasidone group and placebo, respectively).

Adverse events seen in the trial were generally mild. The most commonly reported adverse events for lurasidone (greater than 5% and at least twice the rate of placebo) were akathisia (17.6% vs. 3.1% placebo), somnolence (11.7% vs. 5.5%), parkinsonism (6.8% vs. 0), and increased weight (5.1% vs. 2.4%).

"DSP is committed to the development of lurasidone and we look forward to the completion of our phase 3 clinical trial program and submission of a new drug application to the U.S. FDA," said Masayo Tada, president and chief executive officer, Dainippon Sumitomo Pharma Co., Ltd. "More importantly, we believe that lurasidone will be a valuable new treatment option for patients and physicians in addressing currently unmet needs in the treatment of schizophrenia."

"The development program for lurasidone is intended to establish efficacy for the core symptoms of schizophrenia, characterize its safety profile and explore its effects in the treatment of cognitive impairment and other areas not adequately addressed by current therapies," said Antony Loebel, M.D., vice president of clinical research, Dainippon Sumitomo Pharma America, Inc. "As a large, global trial, the PEARL 1 study is an important new addition to the existing clinical trial database."

PEARL 1 Study Design

This randomized, placebo
'/>"/>

SOURCE Dainippon Sumitomo Pharma Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... Given the narrow initial public offering window, declining venture ... become the exit of choice for many biopharmaceutical companies. In ... was higher, but it still wasn,t the flood of deals ... Another not-so-positive trend for biotech in 2011 was ...
... Independa™ announced today that it has closed ... that surpassed the target of $2.2 million indicating strong ... solutions that enhance independence for older adults. ... top of $1.6 million in seed-round venture capital funding ...
Cached Medicine Technology:Biopharma M&A Trends Hold Steady, But Deals Declined in 2011 2Independa Closes Convertible Note Funding at $2.35 Million 2Independa Closes Convertible Note Funding at $2.35 Million 3
(Date:7/31/2015)... ... 31, 2015 , ... Recently touted by Becker’s Healthcare as ... analytics , Jvion continues to disrupt the predictive analytic and big data market ... and population level illness to drive prevention and better health outcomes. Most recently, ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator ... new applicator in the United States as an upgrade to the CoolSmooth applicator cleared ... applicator required a 2 hour treatment time. The new CoolSmooth Pro reduces the ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Group, Inc. has re-branded their social media profiles to better connect with the ... consumers to communicate, find information, share insights and opinions. The Rally Insurance Group, ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... Rodgers Theatre . Those looking to catch a new and refreshing show on ... won numerous awards and achievements including an Obie Award, Outer Critics Circle Award, Drama ...
(Date:7/31/2015)... Las Vegas, NV (PRWEB) , ... July 31, 2015 , ... ... Vegas bakery is now offering wedding cakes with custom designs, making life ... hard to deliver beautifully designed wedding cakes for each customer who orders one. , ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... has found the first reliable evidence that early detection of ... disease can halve the women,s chances of death from breast ... 18 March) in the cancer journal, Annals of Oncology ... at its early, asymptomatic stage, then the women,s chances of ...
... The Generic Pharmaceutical Association (GPhA) released the following ... regarding the introduction of H.R. 1548, "The Pathway for ... the wrong road for patients looking for safe and ... It is a long route filled with needless ...
... nail pain, too, , , TUESDAY, March 17 (HealthDay News) -- ... seems to help reduce nail psoriasis, according to Italian researchers. ... have nail psoriasis, which includes irregular pitting, salmon-colored patches on ... bed and reddened and often inflamed borders on the nails. ...
... WOODLANDS, Texas, March 17 Standard & Poor,s Rating ... rating to ,B, on Huntsman Corporation,s (NYSE: ... Huntsman reaffirms that its operations are sound and that ... economic recession. Huntsman has met the challenging operating ...
... at the Whitehead Institute for Biomedical Research and the ... (miRNA) capable of directly tamping down the activity of ... to prevent tumor formation, the p53 gene is thought ... , RELEVANCE: The study reports the first time a ...
... of Dental and Craniofacial Research (NIDCR) awarded the American ... Grant in the amount of $250,000, which will fund ... assist approximately 50 students and NIDCR-supported trainees in attending ... & Exhibition for the next five years in the ...
Cached Medicine News:Health News:Early detection of second breast cancers halves women's risk of death 2Health News:Early detection of second breast cancers halves women's risk of death 3Health News:Early detection of second breast cancers halves women's risk of death 4Health News:GPhA Statement on Introduction of H.R. 1548, 'The Pathway for Biosimilars Act' 2Health News:Low-Dose Acitretin May Reduce Nail Psoriasis 2Health News:Huntsman Responds to S&P Action 2Health News:Huntsman Responds to S&P Action 3Health News:MicroRNA undermines tumor suppression 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: